Francesca Zacchi

Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study)Full Length Article sciencedirect.com/science/articl…

Excited to share our review on IL-8 in solid tumors 🧬 A promising non-invasive prognostic biomarker and potential predictor of immunotherapy response/resistance, though still a challenging therapeutic target 🔬 Thanks to the Verona group 🙏🚀cancertreatmentreviews.com/article/S0305-…

Our annual @VHIO #ProstateCancer group retreat yesterday: time to reflect on a strong year, align as a growing team, and charge up for the work ahead in 2026. #TeamScience #CancerResearch - special thanks to @ALymphsLife @criscancer for joining us and to all funding supporters

Out our review published in Critical Reviews in Oncology/Hematology: “The role of therapeutic cancer vaccines in the modern immunotherapy era: State of the art with recent progress and future challenges” sciencedirect.com/science/articl…

🚨 Published our #Review on Senescence in Prostate Cancer! Honored to be part of this collaboration with outstanding colleagues! @quimmateo @julianbrandariz @luisa_bacc76421 @DavidP_Labbe AndreaZivi #Oncology #CancerResearch #Senescence #ProstateCancer sciencedirect.com/science/articl…

🚨 Just published our #MetaAnalysis: Interleukin-8 as a prognostic biomarker in #RenalCellCarcinoma 👉 academic.oup.com/oncolo/article… Grateful to @saramerler, all co-authors, and especially Michele Milella, Head of Oncology, Verona. #Oncology #CancerResearch #Biomarkers #RCC

🔬Call for Papers! 🧬 We are excited to announce that our Frontiers in Oncology (Genitourinary Oncology) Research Topic "Histological and Molecular Subtypes of Prostate Cancer: Biology, Biomarkers, and Therapeutic Implications" is now open for submissions! frontiersin.org/research-topic…

European Urology Oncology (online 28 April 2025). "Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study". sciencedirect.com/science/articl…

Grateful to be involved! Thanks to @AnitaBorsati and her group! onlinelibrary.wiley.com/doi/full/10.11…

🎉I am excited to share our latest publication in Frontiers in Oncology, AvePem Study, a real word study that compare 1L maintainance Avelumab vs 2L Pembrolizumab frontiersin.org/journals/oncol…

Our latest paper is out in @CellRepMed - Functional RAD51-IF to detect HRR defects in #ProstateCancer - exploring correlations between HRR mutations, HRD scores, and RAD51-IF in mPC biopsies #OpenAccess #CancerResearch cell.com/cell-reports-m…

Back from the magic Genève for an amazing #ESMOIO congress with my super ex-colleagues 🔝

@quimmateo @EurUrolOncol @EAntonarakis @Ecastromarcos @AlanBryce9 @heatherhcheng Congrats everyone!! Thanks to @quimmateo for the exceptional guidance and thanks to all the other experts for this incredible collaboration @EAntonarakis @Ecastromarcos @AlanBryce9 @heatherhcheng!!!

Our review on the current state of PARPi development for #prostatecancer is now out in @EurUrolOncol - led by @FrancescaZacc14 + help from several experts in the field sciencedirect.com/science/articl…

🎙️ CALL FOR PAPERS on SPECIAL RESEARCH TOPIC in FRONTIERS IN ONCOLOGY 🧬 Research Topic: Prostate Cancer Senescence: Therapeutic Challenges and Opportunities. Manuscript Summary Submission Deadline 28Feb2025 Manuscript Submission Deadline 30June2025 Link: lnkd.in/dFCj5iZH

Excited to share our publication in European Urology Oncology. It has been an honor to collaborate with leading experts in prostate cancer, and I am incredibly grateful for the exceptional mentorship from Dr. Joaquin Mateo. Full article: lnkd.in/gzkxxniD

Excited to share the findings from the multicenter real-world ARON-3 study, now published in European Urology Oncology! 📌 The analysis highlights that apalutamide in mHSPC remains a safe and effective treatment in real-world practice. 📖 Full article: lnkd.in/d8JJPUPW

📢 #mHNPC, a distinct biological entity? Read our last #review!!! Thanks to @quimmateo and @ArkaitzLab sciencedirect.com/science/articl…

A joint effort with @quimmateo, highlighting the clinical relevance, emerging molecular distinctive features and therapeutic progress in the most aggresive clinical manifestation of prostate cancer. @ContraCancerEs @CIBERONC @ASEICAnews sciencedirect.com/science/articl…

@myESMO Recommendations for clinical reporting of genomics - now published in @Annals_Oncology. We're aiming to advance rational, evidence-based use of genomics in patient care and harmonize biomarker interpretation in cancer treatment annalsofoncology.org/article/S0923-…